

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : MEDERSKI, Werner et al.

Serial No.: 10/583,094

Group Art Unit: 1626

Filed: June 15, 2006

Examiner: SAEED, Kamal A.

For: PROLINYLARYLACETAMIDES

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

In response to the Office Action mailed on March 16, 2009, applicants elect with traverse Group I, claims 1-16, 18-21 and 23, drawn to compounds and compositions. As a species applicants elect with traverse the first compound of claim 16, i.e., the compound of example 1, i.e., 1-N-(4-chlorophenyl)-2-N-{4-[(2-dimethylaminoethanoyl)methylamino]-phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide.

The traversal is on the grounds that the patent office has not established that it would pose an undue burden to examine the full scope of the claimed invention.

Additionally, applicants bring the attention of the Examiner to MPEP § 821.04, Rejoinder, which states that "if the elected invention is directed to the product and the claims directed to the product are subsequently found patentable, process claims [both process of making and using] which either depend from or include all the limitations of the allowable product will be rejoined." If the restriction requirement is maintained at this point, rejoinder of the non-elected claims is respectfully requested at the proper time in accord with the rejoinder provisions of the MPEP.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Csaba Henter/

Csaba Henter, Reg. No. 50,908
Attorney for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: 703-812-5331
Facsimile: 703-243-6410

Attny. Docket No.: Merck-3190

Filed: March 31, 2009

K:\MERCK\3000 - 3999\3190\REPLY RESTR.DOC